Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T07:49:46.634Z Has data issue: false hasContentIssue false
  • English
  • Français

Infantile-onset pompe disease: a tale of two cases

Part of: Metabolic

Published online by Cambridge University Press:  27 January 2020

Drishti Tolani ,
Neha Bansal Open the ORCID record for Neha Bansal [Opens in a new window]  and
Swati Sehgal
Drishti Tolani
Affiliation:
Division of Pediatric Cardiology, The Children’s Hospital of Michigan, Detroit, MI, USA
Neha Bansal*
Affiliation:
Division of Pediatric Cardiology, Children’s Hospital at Montefiore, Bronx, NY, USA
Swati Sehgal
Affiliation:
Division of Pediatric Cardiology, The Children’s Hospital of Michigan, Detroit, MI, USA
*
Author for correspondence: Neha Bansal, Division of Pediatric Cardiology, Children’s Hospital at Montefiore, 3415 Bainbridge Ave- R1, Bronx, NY10467, USA. Tel: 718-741-2313; Fax: (718) 920-4351; E-mail: nbansal@montefiore.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Pompe disease is a type-II glycogen storage disease, and clinical manifestations include hypertrophic cardiomyopathy and generalised muscular hypotonia. Enzyme replacement therapy has proven to be effective in reversing the ventricular hypertrophy. The outcomes are variable depending on time to diagnosis and severity of the cardiac disease. We describe two contrasting cases of patients with infantile-onset Pompe disease. The first child was diagnosed late and had severe cardiac hypertrophy with respiratory decompensation and ventilator dependence and eventual death. The second case was diagnosed at birth with early initiation of therapy resulting in a good outcome. Our cases highlight the importance of early initiation of enzyme replacement therapy to improve clinical outcomes.

Keywords

Infantile Pompe diseasebiventricular hypertrophyenzyme replacement therapy
Type
Brief Report
Information
Cardiology in the Young , Volume 30 , Issue 2 , February 2020 , pp. 275 - 277
Copyright
© Cambridge University Press 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chen, M, Zhang, L, Quan, S.Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev 2017; 11: Cd011539.Google ScholarPubMed
Kishnani, PS, Hwu, WL, Mandel, H, Nicolino, M, Yong, F, Corzo, D.A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006; 148: 671–676.10.1016/j.jpeds.2005.11.033CrossRefGoogle ScholarPubMed
Bali, DS, Goldstein, JL, Banugaria, S, et al.Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 2012; 160c: 40–49.10.1002/ajmg.c.31319CrossRefGoogle ScholarPubMed
Nicolino, M, Byrne, B, Wraith, JE, et al.Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009; 11: 210–219.10.1097/GIM.0b013e31819d0996CrossRefGoogle ScholarPubMed
Levine, JC, Kishnani, PS, Chen, YT, Herlong, JR, Li, JS.Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 2008; 29: 1033–1042.10.1007/s00246-008-9267-3CrossRefGoogle ScholarPubMed
Raben, N, Jatkar, T, Lee, A, et al.Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 2002; 6: 601–608.10.1016/S1525-0016(02)90716-1CrossRefGoogle Scholar
van Gelder, CM, Poelman, E, Plug, I, et al.Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis 2016; 39: 383–390.10.1007/s10545-015-9912-yCrossRefGoogle Scholar
Hordeaux, J, Dubreil, L, Robveille, C, et al.Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun 2017; 5: 66.10.1186/s40478-017-0464-2CrossRefGoogle ScholarPubMed
Chen, LR, Chen, CA, Chiu, SN, et al.Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr 2009; 155: 271–5.e2.10.1016/j.jpeds.2009.03.015CrossRefGoogle ScholarPubMed